Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-02-13
1998-09-29
Grumbling, Matthew V.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514253, 514254, 514259, 544122, 544284, 544293, A61K 31505, A61K 31495, C07D40302, C07D40102
Patent
active
058146300
ABSTRACT:
The invention concerns quinazoline compounds of the formula I ##STR1## wherein Q.sup.1 is a 5- or 6-membered heteroaryl moiety and Q.sup.1 optionally bears up to 3 substituents;
REFERENCES:
patent: 3266990 (1966-08-01), Lutz et al.
patent: 4343940 (1982-08-01), Kreighbaum et al.
patent: 5580870 (1996-12-01), Barker et al.
patent: 5616582 (1997-04-01), Barker
Rewcastle et al., "Tyrosine Kinase Inhibitors. 5. Synthesis and 4-(Phenylamino)quinazolines as Potent Adenosine 5'-Triphosphate Binding Site Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor," J.Med.Chem. 1995, vol. 38, pp. 3482-3487.
Burke, Jr., "Protein-tyrosine kinase inhibitors," Drugs of the Future 1992, vol. 17(2), pp. 119-131.
Spence, "Inhibitors of Tyrosine Kinase Activity as Anticancer Therapeutics: Recent Developments," Current Opinion in Therapeutic Patents, Jan. 1993, Patent Update, Anticancers, etc., pp. 3-9, Current Drugs Ltd ISSN 0962-2594,.
Spada, et al., "Small molecule inhibitors of tyrosine Kinase activity, Exp.Opin.Ther.Patents (1995), 5(8):805-817, Patent Update, Oncologic, Endocrine & Metabolic, Ashley Publications Ltd ISSN 1354-3776.
Bridges, "The current status of tyrosine kinase inhibitors: do the diarylamine inhibitors of the EGF receptor represent a new beginning?," Exp.Opin.Ther.Patents (1995), 5(12): 1245-1257, Editorial, Oncologic, Endocrine & Metabolic, 1995 Ashley Publications Ltd ISSN 1354-3776.
Traxler, et al., "Recent advances in protein tyrosine kinase inhibitors," Drugs of the Future 1995, vol. 20(12, pp. 1261-1274.
Iyer, et al., "Studies in Potential Amoebicides: Part III-Synthesis of .sub.4 -Substituted Amino-8-Hydroxy) Quinazolines & .sub.3 -Substituted 8-Hydroxy(&8-Methoxy)-.sub.4 -Quinazolones," J.Sci.Industr.Res., vol. 15C, Jan. 1956, pp. 1-7.
Derwent Abstract 82-87077, vol. 6, No. 244, Dec. 1982, JP 57-144266, Kobayashi, Sep. 1982, "4-Anilinoquinazoline Derivative, its Preparation and Analgesic and Antiphlogistic Agent Containing Said Derivative as Active Component".
Derwent Abstract 81-28290, JP 56-20577, Feb. 1981, Sankyo and Ube, "4-(N-alkyl:anilino) quinazoline derivs . . . having analgesic and antiinflammatory actions".
Derwent Abstract 84-53835, JP 59-13765, Jan. 1984, Kyorin, "2-(4-Quinazolinyl)amino benzoic acid derivs . . . having analgesic and antiinflammatory activities".
Chem.Abs., vol. 92:76445u, 1980, pp. 674-675, Li, et al.
Chem.Abs., vol. 96:122728w, 1982, p. 695, Lin et al.
Fry et al., "Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase," Science, vol. 265, Aug. 19, 1994, pp. 1093-1095.
Buchdunger, et al., "4,5-Dianilinophthalimide: A protein-throsine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity," Prac.Natl.Acad.Sci., USA, vol. 91, pp. 2334-2338, Mar. 1994, Applied Biological Sciences.
Trinks, et al., "Dianilinophthalimides: Potent and Selective, ATP-Competitive Inhibitors of the EGF-Receptor Protein Tyrosine Kinase," J.Med. Chem. 1994, vol. 37, pp. 1015-1027.
Maguire, et al., "A New Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Substituted Quinoline Derivatives," J.Med.Chem. 1994, vol. 37, pp. 2129-2137.
Dolle, et al., "5,7-Demethoxy-3-(4-pyridinyl)quinoline Is a Potent and Selective Inhibitor of Human Vascular .beta.-Type Platelet-Derived Growth Factor Receptor Tyrosine Kinase," J.Med.Chem. 1994, vol. 37, pp. 2627-2629.
Ward, et al., "Epidermal Growth Factor Receptor Tyrosine Kinase--Investigation of Catalytic Mechanism, Structure-Based Searching and Discovery of a Potent Inhibitor," Biochem.Pharmacology, vol. 48, No. 4, pp. 659-666 (1994).
Ward, et al., "Epidermal Growth Factor Receptor Tyrosine Kinase--Investigation of Catalytic Mechanism, Structure-Based Searching and Discovery of a Potent Inhibitor," Biochem.Pharmacology, vol. 48, No. pp. 659-666 (1994).
Connolly, et al., "Human Vascular Permeablility Factor," J.Bio.Chem., vol. 264, No. 33, Nov. 1989 , pp. 20017-20024.
Cullinan-Bove, et al., "Vascular Endothelial Growth Factor/Vascular Permeablility Factor Expression in the Rat Uterus . . . ," Endocrinology, vol. 133, No. 2, 1993, pp. 829-837.
Fan, et al., "controlling the Vasculature: Angiogenesis, Anti-Angiogenesis . . . ," TiPS Review, vol. 16, Feb. 1995, pp. 57-65.
Folkman, "Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease," Nature Medicine, vol. 1, No. 1, 1995, pp. 27-30.
Jakeman, et al., "Developmental Expression of Binding Sites and Messenger Ribonucleic Acid . . . ," Endocrinology, vol. 133, No. 2, 1993, pp. 848-859.
Kim, et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in Vivo," Nature, vol. 362, Apr. 1993, pp. 841-844.
Kolch, et al., "Regulation of the Expression of the VEGF/VPS and its Receptors: Role in Tumor Angiogenesis," Breast Cancer Research and Treatment, vol. 36, 1995, pp. 139-155.
Senger, et al., "Vascular Permeablility Factor (VPF, VEGF) in Tumor Biology," Cancer and Metastasis Reviews, vol. 12, 1993, pp. 303-324.
Barker Andrew John
Johnstone Craig
Grumbling Matthew V.
Zeneca Limited
LandOfFree
Quinazoline compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazoline compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-686499